The increase in myeloma tumor burden in response to a loss of host-derived MMP-7 is in distinct contrast to previous studies in prostate cancer and breast cancer osteolysis, where tumor burden and osteolytic bone disease were decreased in MMP-7 deficient mice [2, 3]. The gene discussed is MMP7; the disease is plasma cell myeloma.